Optic

Optic's BIOPTIC platform achieves significant breakthroughs in identifying novel drug candidates for 'undruggable' targets, leading to multiple high-value licensing deals and successful clinical progression of partnered assets. This success, coupled with strong revenue growth from collaborations like the $17.5M Vindur Tx deal, pushes valuation to $44M+ (4x current) by 2030, attracting an acquisition by a major pharmaceutical company or a successful Series B/C round at a substantial premium.

Optic continues to secure modest collaborations and licensing agreements, demonstrating the utility of its AI platform in niche areas. Growth is steady but faces intense competition from well-funded incumbents. The company raises subsequent funding rounds at incremental valuations, leading to an eventual acquisition at a slight premium to current valuation, around $16.5M (1.5x current), but with significant dilution for early common shareholders.

Incumbent AI drug discovery companies or major pharma players launch more advanced or cost-effective competing platforms, eroding Optic's competitive edge. Regulatory hurdles and the high cost of drug development lead to slower-than-expected progress, making it difficult to secure follow-on funding. This results in a down round or failure to raise capital, wiping out most common stock value, with the company potentially acquired for its IP at a distressed valuation of $2.2M (0.2x current) or less, far below liquidation preferences.